Ying Chen

Ying Chen

Auto-generated profile, based on publicly available information

Ying Chen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
PLPeihong Lyu
Peihong Lyu
HLHuifang Li
Huifang Li
JWJunzhao Wan
Junzhao Wan
YCYing Chen
Ying Chen
ZZZhen Zhang
Zhen Zhang
Hang MaHang Ma
Hang Ma
Cannabis and its major cannabinoid cannabidiol (CBD) are reported to exhibit anticancer activity against skin tumors. However, the cytotoxic effects of other minor cannabinoids and synthetic CBD derivatives in melanoma are not fully elucidated. Herein, the antiproliferative activity of a panel of phytocannabinoids was screened against murine (B16F10) and human (A375) melanoma cells. CBD was the most cytotoxic natural cannabinoid with respective IC50 of 28.6 and 51.6 μM. Further assessment of the cytotoxicity of synthetic CBD derivatives in B16F10 cells identified two bipiperidinyl group-bearing derivatives (22 and 34) with enhanced cytotoxicity (IC50 = 3.1 and 8.5 μM, respectively). Furthermore, several cell death assays including flow cytometric (for apoptosis and ferroptosis) and lactate dehydrogenase (for pyroptosis) assays were used to characterize the antiproliferative activity of CBD and its bipiperidinyl derivatives. The augmented cytotoxicity of 22 and 34 in B16F10 cells was attributed to their capacity to promote apoptosis (as evidenced by increased apoptotic population). Taken together, this study supports the notion that CBD and its derivatives are promising lead compounds for cannabinoid-based interventions for melanoma management.

11 March 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YZYing Zhang
Ying Zhang
WXWen Xing
Wen Xing
XLXiaoyi Liang
Xiaoyi Liang
ZYZhujuan Yang
Zhujuan Yang
YMYun Ma
Yun Ma
WZWeipei Zhu
Weipei Zhu
Background: Elevated inflammatory markers are commonly linked to poor prognoses in cancer patients, while optimal nutritional status correlates with improved survival outcomes. This study aimed to explore the interplay between nutritional and inflammatory markers and their impact on postoperative outcomes in ovarian cancer patients through a retrospective analysis.Methods: Data were retrospectively retrieved from patients diagnosed with ovarian cancer who required surgical intervention at the Department of Obstetrics and Gynecology. Overall survival (OS) and cancer-specific survival (CSS) were monitored during follow-up. Kaplan-Meier survival curves were employed to assess OS and CSS across different patient cohorts, evaluating the prognostic significance of nutritional and inflammatory markers. Nomograms for predicting OS and CSS at one, three, and five years postoperatively were constructed, followed by external validation.Results: The prognostic nutritional index (PNI) and Naples prognostic score (NPS) exhibited a significant correlation with OS and CSS in postoperative ovarian cancer patients (p < 0.05). Analysis indicated that patients with a PNI > 51.2 demonstrated the most favorable survival outcomes. Furthermore, those with a low-NPS (L-NPS) had notably better survival rates compared to their high-NPS (H-NPS) counterparts. Independent OS predictors included age, PNI, NPS, histological type, tumor size, targeted therapy, and diabetes. Similarly, the CSS prediction model incorporated age, NPS, tumor size, targeted therapy, and diabetes. The nomograms demonstrated robust predictive accuracy for three- and five-year survival, though one-year calibration curves showed limited agreement. Despite slightly reduced external validation performance compared to the initial sample, the model maintained strong predictive capability.Conclusions: The nutritional inflammatory index serves as a key independent prognostic marker for OS and CSS in ovarian cancer patients. Nomograms based on PNI and NPS provide valuable prognostic insights for postoperative management. Incorporating these indices into clinical practice could improve patient stratification and guide personalized treatment plans.